首页> 美国卫生研究院文献>Cancer Cell International >The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
【2h】

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

机译:BH3模拟药物ABT-737诱导甲状腺癌细胞凋亡并与化疗药物协同作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPatients with dedifferentiated and anaplastic thyroid carcinomas that do not take up radioiodine are resistant to chemotherapeutic treatment and external irradiation and thus are difficult to treat. Direct induction of apoptosis is a promising approach in these apoptosis-resistant tumor cells. The BH3 mimetic ABT-737 belongs to a new class of drugs that target anti-apoptotic proteins of the BCL-2 family and facilitate cell death. The purpose of this study was to investigate the effect of ABT-737 alone or in combination with chemotherapeutic drugs on thyroid carcinoma cell lines.
机译:背景不摄取放射性碘的去分化和间变性甲状腺癌的患者对化学治疗和外部照射有抵抗力,因此难以治疗。在这些抗凋亡的肿瘤细胞中直接诱导凋亡是一种有前途的方法。 BH3模拟物ABT-737属于一类新的药物,该药物靶向BCL-2家族的抗凋亡蛋白并促进细胞死亡。这项研究的目的是调查单独或与化疗药物联合使用ABT-737对甲状腺癌细胞系的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号